Enhancing Diabetes and Cardiovascular Management with Continuous Glucose Monitoring (CGM)

This section presents a concise, high-yield summary of the video’s core content, designed as a quick reference for Healthcare Professionals (HCPs).

Note: This content was developed by our editorial team and was not reviewed or endorsed by the video speaker.

Q1: How do cardiovascular complications specifically affect individuals with Type 2 diabetes? 

Individuals with Type 2 diabetes face a significantly higher risk of cardiovascular disease compared to those without diabetes. Specifically, clinical data shows they experience elevated rates of cardiovascular death, coronary death, and cardiovascular hospitalizations.[1]

Q2. What clinical insight does CGM offer beyond laboratory-based markers?

Beyond traditional laboratory markers like HbA1c—which only provide an average and can mask extreme daily highs and lows [4,5] —  CGM reveals the true distribution of glucose and provides critical metrics on Glycaemic Variability (GV). High glycemic variability is directly associated with acute oxidative stress, retinopathy, neuropathy, and a higher risk of severe hypoglycemia. Additionally, CGM offers actionable, real-time trend data that drives immediate behavioral adjustments (like eating fewer carbohydrates) and provides clinicians with the long-range data needed for safe treatment titration. [7,9]  Identical HbA1c values can reflect markedly different glucose profiles with varying hypoglycemia exposure, post-prandial excursions, and diurnal trends. These patterns have distinct biological consequences, particularly where variability drives oxidative stress and microvascular damage.[4,5] 

Q3. Why does advanced chronic liver disease (CKD) necessitate alternative glycemic monitoring approaches like CGM?

 In advanced CKD, traditional laboratory markers become highly unreliable. HbA1c levels are heavily distorted by factors such as altered red cell turnover, anemia, and iron supplementation, whereas alternatives like fructosamine are unreliable in the presence of proteinuria. As CKD progresses, the correlation between HbA1c and the CGM-derived Glucose Management Indicator (GMI) steadily decreases, making CGM data increasingly necessary for accurate monitoring.[8]

Q4. What is clinically notable about CGM effects in T2D basal insulin therapy?
In the MOBILE study, patients using CGM saw a significant drop in HbA1c (from 9.1% to 8.0%) without any change in their insulin dose, suggesting the improvement was driven by behavioral change rather than insulin escalation [9]

Q5. How does AI-enabled CGM address workflow gaps in diabetes care and influence broader cardiometabolic management?

AI-enabled CGM shifts glucose monitoring from retrospective review to predictive, real-time decision support. By forecasting glucose trends and generating actionable nudges, it helps reduce clinician data-interpretation burden during short consultations and alleviates patient anxiety associated with reactive glucose checking. At a systems level, integrating AI with CGM supports decentralized and remote care models similar to those used in heart failure and chronic kidney disease management. This approach enables telemonitoring, may reduce acute metabolic admissions, and can facilitate earlier initiation and optimization of organ-protective therapies by maintaining greater metabolic stability. [11,12]

Q6. How will the integration of AI-enabled CGM enhance self-management of diabetes and personalise management plans?

Currently, standard CGMs provide only instantaneous glucose readings and reactive alarms when glucose levels are already too high or too low, which forces patients to act after an event has already started. AI-enabled CGMs transform this process by offering real-time glucose forecasting, such as predicting a patient’s glucose 2 hours into the future or specifically predicting nocturnal hypoglycemia before they go to sleep. 

Looking forward, the future of AI in CGM will shift the user experience from reactive alarms to pre-emptive nudging, utilizing advanced models that can process simultaneous inputs and even use computer vision for complex meal recognition.[11,12]